Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381253 | 0.86 | LOXL2 (0.53) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL4660280 | 0.83 | LOXL2 (0.53) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL29383990 | 0.83 | LOXL2 (0.53) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL29365671 | 0.83 | LOXL2 (0.56) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL49270 | 0.83 | LOXL2 (0.56) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL31336079 | 0.83 | LOXL2 (0.56) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL1383201 | 0.82 | MTNR1A (0.51) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL3659732 | 0.82 | MTNR1A (0.51) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| SCHEMBL31511816 | 0.81 | LOXL2 (0.55) | LOXL2NLRP3MTNR1AMTNR1BIDO1 | |
| Water SCHEMBL30025993 | 0.81 | LOXL2 (0.55) | LOXL2NLRP3MTNR1AMTNR1BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367847-B2 | Production of monatin enantiomers | CARGILL, INCORPORATED (US) | 2013-02-05 | — | — | US | claimed |
| EP-2209767-A2 | PRODUCTION OF MONATIN ENANTIOMERS | Cargill, Incorporated (US) | 2010-07-28 | — | — | EP | claimed |
| WO-2009044245-A2 | PRODUCTION OF MONATIN ENANTIOMERS | CARGILL, INCORPORATED (US) | 2009-04-09 | — | — | WO | claimed |
| US-20090088577-A1 | PRODUCTION OF MONATIN ENANTIOMERS | CARGILL, INCORPORATED | 2009-04-02 | — | — | US | claimed |
| US-8367847-B2 | Production of monatin enantiomers | CARGILL, INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2209767-A2 | PRODUCTION OF MONATIN ENANTIOMERS | Cargill, Incorporated (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009044245-A2 | PRODUCTION OF MONATIN ENANTIOMERS | CARGILL, INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090088577-A1 | PRODUCTION OF MONATIN ENANTIOMERS | CARGILL, INCORPORATED | 2009-04-02 | — | — | US | disclosed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | disclosed |
| US-6946115-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6294672-B1 | FOR THERAPY OF DIABETES, AND OTHER DISEASES WHERE THE INHIBITION OF GLUCONEOGENESIS, CONTROL OF BLOOD GLUCOSE LEVELS, REDUCTION IN GLYCOGEN STORES, OR REDUCTION IN INSULIN LEVELS IS BENEFICIAL | METABASIS THERAPEUTICS, INC. | 2001-09-25 | — | — | US | disclosed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| US-6054587-A | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| WO-1998039342-A1 | NOVEL INDOLE AND AZAINDOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | LOXL2 258/4885NLRP3 4075/4885MTNR1A 1445/4885 |
| US-20090088577-A1 | PRODUCTION OF MONATIN ENANTIOMERS | MON2, CIAPIN1, SI | LOXL2 4376/4885NLRP3 477/4885MTNR1A 499/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | LOXL2 350/4885NLRP3 4200/4885MTNR1A 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.